





Table of recommended groups for COVID-19 autumn booster and flu vaccine

Age and Cohort	COVID-19 Autumn Booster (for those who have completed primary course and at least one booster dose)	Flu Vaccine ⁴
65 and older	Recommended for all (at least 6 months since last booster dose or SARS-CoV-2 infection) ¹	Recommended for all
50 to 64 years	Recommended for all (at least 6 months since last booster dose or SARS-CoV-2 infection) ¹	Recommended for: -those at increased risk of influenza- related complications ⁵
18 to 49 years	-those with immunocompromise associated with a suboptimal response to vaccination² (at least 6 months since last booster dose or SARS-CoV-2 infection)¹ -those with medical conditions associated with a higher risk of COVID-19 hospitalisation, severe disease or death³ (at least 9 months since last booster dose or SARS-CoV-2 infection)¹ For those healthy aged 18-49 years and who are up to date with their vaccines (primary schedule and first booster) - an autumn booster vaccine is not routinely recommended - access to an autumn booster vaccine should be available for those who, following discussion of their reasons with a health care provider (e.g., GP, pharmacist or vaccination centre),request vaccination	Recommended for: -those at increased risk of influenza- related complications ⁵







5 to 17 years	Recommended for: -those with immunocompromise associated with a suboptimal response to vaccination ² (at least 6 months since last booster dose or SARS-CoV-2 infection) ¹	
	-those with medical conditions associated with a higher risk of COVID-19 hospitalisation, severe disease or death ³ (at least 9 months since last booster dose or SARS-CoV-2 infection) ¹	Recommended for all
2 to 4 years	Not recommended	Recommended for all
6 to 23 months	Not recommended	Recommended for those at increased risk of influenza- related complications ⁵
Healthcare Workers	Recommended for all (recommended intervals are age related as outlined in NIAC chapter 5a Table 5a.1.)	Recommended for all
Pregnancy	A COVID-19 booster dose is recommended at least once in pregnancy. -If no previous booster: booster recommended at least 4 months after last COVID-19 vaccine dose or SARS-CoV-2 infection ¹ -If received a booster prior to pregnancy: booster recommended at least 6 months after last COVID-19 vaccine dose or SARS-CoV-2 infection ¹	Recommended at any stage of pregnancy







underlying chronic health condition or have Down		
Carers and household contacts of people with		
Residents of nursing homes and other long stay institutions		Recommended for all
	-Booster doses can be given at any stage in pregnancy but ideally should be given between 20-34 weeks. -If it is more than 12 months since previous COVID-19 vaccine dose or SARS-CoV-2 infection: booster earlier in pregnancy should be considered. -For those who are pregnant and are immunocompromised, a second booster dose within the same pregnancy may be considered if six months has elapsed since their last booster dose or SARS-CoV-2 infection	

- 1. In exceptional circumstances or for operational reasons a minimum interval of three months may be used
- 2. Conditions in the shaded areas of Table 5a.2 of the immunisation guidelines (NIAC Chapter 5a) may be associated with a suboptimal response to vaccines
- 3. Medical conditions associated with a higher risk of COVID-19 hospitalisation, severe disease or death are outlined in Table 5a.2 of the immunisation guidelines
- 4. See appendix 1 for groups recommended a two dose schedule of flu vaccine
- 5. See appendix 2 for groups at increased risk of influenza- related complications







Appendix 1

Those recommended a two dose schedule of Flu vaccine For LAIV

• 2 doses, 4 weeks apart if clinically at risk and 2-8 years and first time receiving any influenza vaccine

For QIV

- 2 Doses four weeks apart for children aged 6 months to <9 years if receiving influenza vaccine for the first time.
- 2 Doses four weeks apart if post haematopoeitic stem cell or solid organ transplant and receiving influenza vaccine for the first time post-transplant.
- Cancer patients who receive the vaccine while on chemotherapy and who complete their treatment in the same season require two
 doses with the 2nd dose at least 4 weeks after completion of chemotherapy and at least 4 weeks after 1st dose (regardless of influenza
 vaccination in previous seasons).

Appendix 2

Those at increased risk of influenza- related complications who are recommended Influenza vaccine

- Those aged 6 to 23 months and aged 18-64 years with:
 - Chronic heart disease including acute coronary syndrome
 - Chronic liver disease
 - o Chronic neurological disease including multiple sclerosis, hereditary and degenerative disorders of the central nervous system
 - Chronic renal failure
 - Cancer patients
 - Chronic respiratory disease, including chronic obstructive pulmonary disease, cystic fibrosis, moderate or severe asthma or bronchopulmonary dysplasia
 - o Diabetes mellitus
 - Down syndrome
 - Haemoglobinopathies
 - o Immunosuppression due to disease or treatment, including asplenia or splenic dysfunction and cancer patients
 - Morbid obesity, i.e. body mass index of 40 or over
 - o On long-term aspirin therapy (because of the risk of Reyes syndrome)
 - With any condition (e.g. cognitive dysfunction, spinal cord injury, seizure disorder, or other neuromuscular disorder) that can compromise respiratory function especially those attending special schools/day centres
 - With moderate to severe neurodevelopmental disorders such as cerebral palsy and intellectual disability